<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title></title>
	<atom:link href="http://www.drugepi.org/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.drugepi.org</link>
	<description>Division of Pharmacoepidemiology</description>
	<lastBuildDate>Wed, 22 Feb 2012 15:04:53 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator>
		<item>
		<title>DEcIDE Methods Center CER Scan (February 2012)</title>
		<link>http://www.drugepi.org/recently-at-dope/decide-methods-center-cer-scan-february-2012/</link>
		<comments>http://www.drugepi.org/recently-at-dope/decide-methods-center-cer-scan-february-2012/#comments</comments>
		<pubDate>Thu, 09 Feb 2012 18:17:09 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[DEcIDE CER Scans]]></category>

		<guid isPermaLink="false">http://www.drugepi.org/?p=1665</guid>
		<description><![CDATA[<p>The DEcIDE Methods Center publishes a monthly literature scan of current articles of interest to the field of comparative effectiveness research.</p> <p>You can find them all <a href="../research/dmc">here</a>.</p> February 2012 <p></a></p> <p>CER Scan [Epub ahead of print] </p> Am J Epidemiol. 2012 Jan 5. [Epub ahead of print] <p>Bias in Observational Studies of Prevalent Users: [...]]]></description>
			<content:encoded><![CDATA[<p>The DEcIDE Methods Center publishes a monthly literature scan of current articles of interest to the field of comparative effectiveness research.</p>
<p>You can find them all <a href="../research/dmc">here</a>.</p>
<h4 style="margin-top: 25px;">February 2012</h4>
<p></a></p>
<p><strong><u>CER Scan [Epub ahead of print] </u></strong></p>
<ol>
<li>Am J Epidemiol. 2012 Jan 5. [Epub  ahead of print]</li>
<p><strong>Bias in Observational Studies of Prevalent Users: Lessons for  Comparative Effectiveness Research From a Meta-Analysis of Statins.</strong> Danaei G, Tavakkoli M, Hern&aacute;n MA.</p>
<p>Randomized  clinical trials (RCTs) are usually the preferred strategy with which to  generate evidence of comparative effectiveness, but conducting an RCT is not  always feasible. Though observational studies and RCTs often provide comparable  estimates, the questioning of observational analyses has recently intensified  because of randomized-observational discrepancies regarding the effect of  postmenopausal hormone replacement therapy on coronary heart disease.  Reanalyses of observational data that excluded prevalent users of hormone  replacement therapy led to attenuated discrepancies, which begs the question of  whether exclusion of prevalent users should be generally recommended. In the  current study, the authors evaluated the effect of excluding prevalent users of  statins in a meta-analysis of observational studies of persons with  cardiovascular disease. The pooled, multivariate-adjusted mortality hazard  ratio for statin use was 0.77 (95% confidence interval (CI): 0.65, 0.91) in 4  studies that compared incident users with nonusers, 0.70 (95% CI: 0.64, 0.78)  in 13 studies that compared a combination of prevalent and incident users with  nonusers, and 0.54 (95% CI: 0.45, 0.66) in 13 studies that compared prevalent  users with nonusers. The corresponding hazard ratio from 18 RCTs was 0.84 (95%  CI: 0.77, 0.91). It appears that the greater the proportion of prevalent statin  users in observational studies, the larger the discrepancy between  observational and randomized estimates. <br />
  PMID:22223710</p>
</ol>
<p><strong><u>CER Scan [published within the last 30 days]</u></strong></p>
<ol>
<li>J  Clin Epidemiol. 2012 Feb;65(2):132-7. Epub 2011 Aug 12.</li>
<p><strong>The &quot;best balance&quot;  allocation led to optimal balance in cluster-controlled trials. </strong>de Hoop E, Teerenstra S, van Gaal BG,  Moerbeek M, Borm GF.<strong> </strong><em>Department of Epidemiology, Biostatistics  and HTA, 133, Radboud University Nijmegen  Medical Centre, PO Box   9101, 6500 HB Nijmegen, The Netherlands.</em><strong></strong></p>
<p>OBJECTIVE:  Balance of prognostic factors between treatment groups is desirable because it  improves the accuracy, precision, and credibility of the results. In cluster-controlled  trials, imbalance can easily occur by chance when the number of cluster is  small. If all clusters are known at the start of the study, the &quot;best  balance&quot; allocation method (BB) can be used to obtain optimal balance. This  method will be compared with other allocation methods.<br />
  STUDY  DESIGN AND SETTING: We carried out a simulation study to compare the balance  obtained with BB, minimization, unrestricted randomization, and matching for  four to 20 clusters and one to five categorical prognostic factors at cluster level.<br />
  RESULTS: BB  resulted in a better balance than randomization in 13-100% of the situations,  in 0-61% for minimization, and in 0-88% for matching. The superior performance  of BB increased as the number of clusters and/or the number of factors  increased.<br />
  CONCLUSION:  BB results in a better balance of prognostic factors than randomization,  minimization, stratification, and matching in most situations. Furthermore, BB  cannot result in a worse balance of prognostic factors than the other methods. Copyright  &copy; 2012 Elsevier Inc. All rights reserved.<br />
  PMID:  21840173&nbsp; </p>
<li>Clin Pharmacol Ther. 2012 Feb;91(2):165-7. doi:  10.1038/clpt.2011.208. </li>
<p><strong>Challenges in designing comparative-effectiveness trials for  antidepressants.</strong> Leon AC. <em>Departments  of Psychiatry and Public Health, Weill Cornell Medical   College, New York, New York, USA.</em></p>
<p>Comparative-effectiveness antidepressant trials  offer promise to provide empirical evidence for clinicians choosing among  interventions. Whether such trials posit superiority or noninferiority (NI)  hypotheses, they pose formidable challenges. For instance, if meaningful  antidepressant differences are seen in comparative-superiority trials, they  will be small. NI hypothesis testing, on the other hand, requires an a priori  NI margin and evidence of trial assay sensitivity. Either design demands  unusually large samples, which could render such trials infeasible.<br />
  PMID: 22261683&nbsp;  [PubMed - in process] </p>
</ol>
<p><strong><u>FEBRUARY THEME: Selected Methods Manuscripts from the Pharmacoepidemiology  and Drug Safety </u></strong><strong><u>Mini-Sentinel Supplement </u></strong></p>
<ol>
<li><strong>The U.S. Food and Drug Administration&#8217;s  Mini-Sentinel program: status and direction (pages 1&ndash;8)</strong>. Platt R, Carnahan RM, Brown JS, Chrischilles E,  Curtis LH, Hennessy S, Nelson JC, Racoosin JA, Robb M, Schneeweiss S, Toh S, Weiner  MG. Article first published online: 19 JAN 2012 | DOI: 10.1002/pds.2343</li>
<p>The  Mini-Sentinel is a pilot program that is developing methods, tools, resources,  policies, and procedures to facilitate the use of routinely collected  electronic healthcare data to perform active surveillance of the safety of  marketed medical products, including drugs, biologics, and medical devices. The  U.S. Food and Drug Administration (FDA) initiated the program in 2009 as part  of its Sentinel Initiative, in response to a Congressional mandate in the FDA  Amendments Act of 2007. After two years, Mini-Sentinel includes 31 academic and  private organizations. It has developed policies, procedures, and technical  specifications for developing and operating a secure distributed data system  comprised of separate data sets that conform to a common data model covering  enrollment, demographics, encounters, diagnoses, procedures, and ambulatory  dispensing of prescription drugs. The distributed data sets currently include  administrative and claims data from 2000 to 2011 for over 300 million  person-years, 2.4 billion encounters, 38 million inpatient hospitalizations,  and 2.9 billion dispensings. Selected laboratory results and vital signs data  recorded after 2005 are also available. There is an active data quality  assessment and characterization program, and eligibility for medical care and  pharmacy benefits is known. Systematic reviews of the literature have assessed  the ability of administrative data to identify health outcomes of interest, and  procedures have been developed and tested to obtain, abstract, and adjudicate  full-text medical records to validate coded diagnoses. Mini-Sentinel has also  created a taxonomy of study designs and analytical approaches for many commonly  occurring situations, and it is developing new statistical and epidemiologic  methods to address certain gaps in analytic capabilities. Assessments are  performed by distributing computer programs that are executed locally by each  data partner. The system is in active use by FDA, with the majority of  assessments performed using customizable, reusable queries (programs).  Prospective and retrospective assessments that use customized protocols are  conducted as well. To date, several hundred unique programs have been  distributed and executed. Current activities include active surveillance of  several drugs and vaccines, expansion of the population, enhancement of the  common data model to include additional types of data from electronic health  records and registries, development of new methodologic capabilities, and  assessment of methods to identify and validate additional health outcomes of  interest. Copyright &copy; 2012 John Wiley &amp; Sons, Ltd.</p>
<p>Link to Free PDF: <a href="http://onlinelibrary.wiley.com/doi/10.1002/pds.2343/pdf" target="_blank">http://onlinelibrary.wiley.com/doi/10.1002/pds.2343/pdf</a></p>
<li><strong>A policy framework for public health uses  of electronic health data (pages 18&ndash;22).</strong> McGraw D, Rosati K, Evans B. Article first published  online: 19 JAN 2012 | DOI: 10.1002/pds.2319</li>
<p>Successful  implementation of a program of active safety surveillance of drugs and medical  products depends on public trust. This article summarizes how the initial pilot  phase of the FDA&#8217;s Sentinel Initiative, Mini-Sentinel, is being conducted in compliance  with applicable federal and state laws. The article also sets forth the  attributes of Mini-Sentinel that enhance privacy and public trust, including  the use of a distributed data system (where identifiable information remains at  the data partners) and the adoption by participants of additional mandatory  policies and procedures implementing fair information practices. The authors  conclude by discussing the implications of this model for other types of  secondary health data uses. Copyright &copy; 2012 John Wiley &amp; Sons, Ltd.</p>
<p>Link to Free PDF: <a href="http://onlinelibrary.wiley.com/doi/10.1002/pds.2319/pdf" target="_blank">http://onlinelibrary.wiley.com/doi/10.1002/pds.2319/pdf</a></p>
<li><strong>Design considerations, architecture, and  use of the Mini-Sentinel distributed data system (pages 23&ndash;31).</strong> Curtis LH,Weiner MG, Boudreau DM, Cooper WO,  Daniel GW, Nair VP, Raebel MA, Beaulieu NU, Rosofsky R, Woodworth TS, Brown JS.  Article first published online: 19 JAN 2012 | DOI: 10.1002/pds.2336</li>
<p>Purpose: We  describe the design, implementation, and use of a large, multiorganizational  distributed database developed to support the Mini-Sentinel Pilot Program of  the US Food and Drug Administration (FDA). As envisioned by the US FDA, this  implementation will inform and facilitate the development of an active  surveillance system for monitoring the safety of medical products (drugs,  biologics, and devices) in the USA. <br />
  Methods: A  common data model was designed to address the priorities of the Mini-Sentinel  Pilot and to leverage the experience and data of participating organizations  and data partners. A review of existing common data models informed the  process. Each participating organization designed a process to extract,  transform, and load its source data, applying the common data model to create  the Mini-Sentinel Distributed Database. Transformed data were characterized and  evaluated using a series of programs developed centrally and executed locally  by participating organizations. A secure communications portal was designed to  facilitate queries of the Mini-Sentinel Distributed Database and transfer of  confidential data, analytic tools were developed to facilitate rapid response  to common questions, and distributed querying software was implemented to  facilitate rapid querying of summary data. <br />
  Results: As  of July 2011, information on 99&#8201;260&#8201;976 health plan members was  included in the Mini-Sentinel Distributed Database. The database includes  316&#8201;009&#8201;067 person-years of observation time, with members  contributing, on average, 27.0&#8201;months of observation time. All data  partners have successfully executed distributed code and returned findings to  the Mini-Sentinel   Operations Center. <br />
  Conclusion:  This work demonstrates the feasibility of building a large, multiorganizational  distributed data system in which organizations retain possession of their data  that are used in an active surveillance system. Copyright &copy; 2012 John Wiley  &amp; Sons, Ltd.</p>
<p>Link to Free PDF: <a href="http://onlinelibrary.wiley.com/doi/10.1002/pds.2336/pdf" target="_blank">http://onlinelibrary.wiley.com/doi/10.1002/pds.2336/pdf</a></p>
<li><strong>Using high-dimensional propensity scores  to automate confounding control in a distributed medical product safety  surveillance system (pages 41&ndash;49).</strong> Rassen JA,  Schneeweiss S. Article first published online: 19 JAN 2012 | DOI:  10.1002/pds.2328</li>
<p>Distributed  medical product safety monitoring systems such as the Sentinel System, to be  developed as a part of Food and Drug Administration&#8217;s Sentinel Initiative, will  require automation of large parts of the safety evaluation process to achieve  the necessary speed and scale at reasonable cost without sacrificing validity.  Although certain functions will require investigator intervention, confounding  control is one area that can largely be automated. The high-dimensional  propensity score (hd-PS) algorithm is one option for automated confounding  control in longitudinal healthcare databases. In this article, we discuss the  use of hd-PS for automating confounding control in sequential database cohort  studies, as applied to safety monitoring systems. In particular, we discuss the  robustness of the covariate selection process, the potential for over- or  under-selection of variables including the possibilities of M-bias and Z-bias,  the computation requirements, the practical considerations in a federated  database network, and the cases where automated confounding adjustment may not  function optimally. We also outline recent improvements to the algorithm and  show how the algorithm has performed in several published studies. We conclude  that despite certain limitations, hd-PS offers substantial advantages over  non-automated alternatives in active product safety monitoring systems.  Copyright &copy; 2012 John Wiley &amp; Sons, Ltd.</p>
<p>Link to Free PDF: <a href="http://onlinelibrary.wiley.com/doi/10.1002/pds.2328/pdf" target="_blank">http://onlinelibrary.wiley.com/doi/10.1002/pds.2328/pdf</a></p>
<li><strong>When should case-only designs be used for  safety monitoring of medical products? (pages 50&ndash;61).</strong> Maclure M, Fireman B, Nelson JC, Hua W, Shoaibi A,  Paredes A, Madigan D. Article first published online: 19 JAN 2012 | DOI:  10.1002/pds.2330</li>
<p>Purpose: To  assess case-only designs for surveillance with administrative databases. <br />
  Methods: We  reviewed literature on two designs that are observational analogs to crossover  experiments: the self-controlled case series (SCCS) and the case-crossover  (CCO) design. <br />
  Results:  SCCS views the &lsquo;experiment&rsquo; prospectively, comparing outcome risks in windows  with different exposures. CCO retrospectively compares exposure frequencies in  case and control windows. The main strength of case-only designs is they entail  self-controlled analyses that eliminate confounding and selection bias by  time-invariant characteristics not recorded in healthcare databases. They also  protect privacy and are computationally efficient, as they require fewer  subjects and variables. They are better than cohort designs for investigating  transient effects of accurately recorded preventive agents, for example,  vaccines. They are problematic if timing of self-administration is sporadic and  dissociated from dispensing times, for example, analgesics. They tend to have  less exposure misclassification bias and time-varying confounding if exposures  are brief. Standard SCCS designs are bidirectional (using time both before and  after the first exposure event), so they are more susceptible than CCOs to  reverse-causality bias, including immortal-time bias. This is true also for  sequence symmetry analysis, a simplified SCCS. Unidirectional CCOs use only  time before the outcome, so they are less affected by reverse causality but  susceptible to exposure-trend bias. Modifications of SCCS and CCO partially  deal with these biases. The head-to-head comparison of multiple products helps  to control residual biases. <br />
  Conclusion:  The case-only analyses of intermittent users complement the cohort analyses of  prolonged users because their different biases compensate for one another.  Copyright &copy; 2012 John Wiley &amp; Sons, Ltd.</p>
<p>Link to Free PDF: <a href="http://onlinelibrary.wiley.com/doi/10.1002/pds.2330/pdf" target="_blank">http://onlinelibrary.wiley.com/doi/10.1002/pds.2330/pdf</a></p>
<li><strong>Challenges in the design and analysis of  sequentially monitored postmarket safety surveillance evaluations using  electronic observational health care data (pages 62&ndash;71).</strong> Nelson JC, Cook AJ, Yu O, Dominguez C, Zhao S,  Greene SK, Fireman BH, Jacobsen SJ, Weintraub ES, Jackson LA. Article first  published online: 19 JAN 2012 | DOI: 10.1002/pds.2324</li>
<p>Purpose:  Many challenges arise when conducting a sequentially monitored medical product  safety surveillance evaluation using observational electronic data captured  during routine care. We review existing sequential approaches for potential use  in this setting, including a continuous sequential testing method that has been  utilized within the Vaccine Safety Datalink (VSD) and group sequential methods,  which are used widely in randomized clinical trials. <br />
  Methods:  Using both simulated data and preliminary data from an ongoing VSD evaluation,  we discuss key sequential design considerations, including sample size and duration  of surveillance, shape of the signaling threshold, and frequency of interim  testing. <br />
  Results and  Conclusions: All designs control the overall Type 1 error rate across all tests  performed, but each yields different tradeoffs between the probability and  timing of true and false positive signals. Designs tailored to monitor efficacy  outcomes in clinical trials have been well studied, but less consideration has  been given to optimizing design choices for observational safety settings,  where the hypotheses, population, prevalence and severity of the outcomes,  implications of signaling, and costs of false positive and negative findings  are very different. Analytic challenges include confounding, missing and  partially accrued data, high misclassification rates for outcomes presumptively  defined using diagnostic codes, and unpredictable changes in dynamically  accessed data over time (e.g., differential product uptake). Many of these  factors influence the variability of the adverse events under evaluation and, in  turn, the probability of committing a Type 1 error. Thus, to ensure proper Type  1 error control, planned sequential thresholds should be adjusted over time to  account for these issues. Copyright &copy; 2012 John Wiley &amp; Sons, Ltd.</p>
<p>Link to Free PDF: <a href="http://onlinelibrary.wiley.com/doi/10.1002/pds.2324/pdf" target="_blank">http://onlinelibrary.wiley.com/doi/10.1002/pds.2324/pdf</a></p>
<li><strong>Statistical approaches to group sequential  monitoring of postmarket safety surveillance data: current state of the art for  use in the Mini-Sentinel pilot (pages 72&ndash;81).</strong> Cook AJ, Tiwari RC, Wellman RD, Heckbert SR, Li L,  Heagerty P, Marsh T, Nelson JC. Article first published online: 19 JAN 2012 |  DOI: 10.1002/pds.2320</li>
<p>Purpose:  This manuscript describes the current statistical methodology available for  active postmarket surveillance of pre-specified safety outcomes using a  prospective incident user concurrent control cohort design with existing  electronic healthcare data. <br />
  Methods:  Motivation of the active postmarket surveillance setting is provided using the  Food and Drug Administration&#8217;s Mini-Sentinel Pilot as an example. Four  sequential monitoring statistical methods are presented including the  Lan&ndash;Demets error spending approach, a matched likelihood ratio test statistic  approach with the binomial MaxSPRT as a special case, the conditional  sequential sampling procedure with stratification, and a generalized estimating  equation regression approach using permutation. Information on the assumptions,  limitations, and advantages of each approach is provided, including how each  method defines sequential monitoring boundaries, what test statistic is used,  and how robust it is to settings of rare events or frequent testing. <br />
  Results: A  hypothetical example of how the approaches could be applied to data comparing a  medical product of interest, drug A, to a concurrent control drug, drug B, is  presented including providing the type of information one would have available  for monitoring such drugs. Copyright &copy; 2012 John Wiley &amp; Sons, Ltd.</p>
<p>Link to Free PDF: <a href="http://onlinelibrary.wiley.com/doi/10.1002/pds.2320/pdf" target="_blank">http://onlinelibrary.wiley.com/doi/10.1002/pds.2320/pdf</a></p>
<li><strong><a href="http://onlinelibrary.wiley.com/doi/10.1002/pds.2337/abstract">A protocol  for active surveillance of acute myocardial infarction in association with the  use of a new antidiabetic pharmaceutical agent (pages 282&ndash;290)</a>.</strong> Fireman B, Toh S, Butler MG, Go AS, Joffe HV,  Graham DJ, Nelson JC, Daniel GW, Selby JV. Article first published online: 19  JAN 2012 | DOI: 10.1002/pds.2337</li>
<p>Purpose: To  describe a protocol for active surveillance of acute myocardial infarction  (AMI) in users of a recently approved oral antidiabetic medication,  saxagliptin, and to provide the rationale for decisions made in drafting the  protocol. <br />
  Methods: A  new-user cohort design is planned for evaluating data from at least four  Mini-Sentinel data partners from 1 August 2009 (following US Food and Drug  Administration&#8217;s approval of saxagliptin) through mid-2013. New users of  saxagliptin will be compared in separate analyses with new users of  sitagliptin, pioglitazone, long-acting insulins, and second-generation  sulfonylureas. Two approaches to controlling for confounding will be evaluated:  matching by exposure propensity score and stratification by AMI risk score. The  primary analyses will use Cox regression models specified in a way that does  not require pooling of patient-level data from the data partners. The Cox  models are fit to summarized data on risk sets composed of saxagliptin users  and similar comparator users at the time of an AMI. Secondary analyses will use  alternative methods including Poisson regression and will explore whether  further adjustment for covariates available only at some data partners (e.g.,  blood pressure) modifies results. <br />
  Results: The  results of this study are pending. <br />
  Conclusions:  The proposed protocol describes a design for surveillance to evaluate the  safety of a newly marketed agent as postmarket experience accrues. It uses data  from multiple partner organizations without requiring sharing of patient-level  data and compares alternative approaches to controlling for confounding. It is  hoped that this initial active surveillance project of the Mini-Sentinel will  provide insights that inform future population-based surveillance of medical  product safety. Copyright &copy; 2012 John Wiley &amp; Sons, Ltd.</p>
<p>Link to Free PDF: <a href="http://onlinelibrary.wiley.com/doi/10.1002/pds.2337/pdf" target="_blank">http://onlinelibrary.wiley.com/doi/10.1002/pds.2337/pdf</a><strong><u> </u></strong></p>
</ol>
]]></content:encoded>
			<wfw:commentRss>http://www.drugepi.org/recently-at-dope/decide-methods-center-cer-scan-february-2012/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Aaron Kesselheim Examines Path to More Affordable and Effective Drugs</title>
		<link>http://www.drugepi.org/recently-at-dope/aaron-kesselheim-examines-path-to-more-affordable-and-effective-drugs/</link>
		<comments>http://www.drugepi.org/recently-at-dope/aaron-kesselheim-examines-path-to-more-affordable-and-effective-drugs/#comments</comments>
		<pubDate>Fri, 03 Feb 2012 20:50:09 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Faculty Accomplishments]]></category>
		<category><![CDATA[Faculty in the Media]]></category>

		<guid isPermaLink="false">http://www.drugepi.org/?p=1635</guid>
		<description><![CDATA[<p>Aaron Kesselheim, MD, JD, MPH, is featured in the Robert Wood Johnson Foundation (RWJF) &#8220;Human Capital&#8221; portfolio, which highlights research accomplishments of RWJF grantees. In it, Dr. Kesselheim&#8217;s research on policies to improve patient care is profiled.</p> <p><a href="http://www.rwjf.org/pr/product.jsp?id=73907&#38;cid=XEM_205596" target="_blank">Investigator Examines Path to More Affordable and Effective Drugs</a></p>]]></description>
			<content:encoded><![CDATA[<p>Aaron Kesselheim, MD, JD, MPH, is featured in the Robert Wood Johnson Foundation (RWJF) &#8220;Human Capital&#8221; portfolio, which highlights research accomplishments of RWJF grantees.  In it, Dr. Kesselheim&#8217;s research on policies to improve patient care is profiled.</p>
<p><a href="http://www.rwjf.org/pr/product.jsp?id=73907&amp;cid=XEM_205596" target="_blank">Investigator Examines Path to More Affordable and Effective Drugs</a></p>
]]></content:encoded>
			<wfw:commentRss>http://www.drugepi.org/recently-at-dope/aaron-kesselheim-examines-path-to-more-affordable-and-effective-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Steven Brunelli on Iodide and Thyroid Disease</title>
		<link>http://www.drugepi.org/recently-at-dope/brunelli-iodide-thyroid/</link>
		<comments>http://www.drugepi.org/recently-at-dope/brunelli-iodide-thyroid/#comments</comments>
		<pubDate>Mon, 23 Jan 2012 19:00:46 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Faculty in the Media]]></category>

		<guid isPermaLink="false">http://www.drugepi.org/?p=1531</guid>
		<description><![CDATA[<p>Steven Brunelli, MD, MSCE, and colleagues from Harvard Medical School and Brigham and Women&#8217;s Hospital were featured in the New York times for their latest research, published in the January 23rd, 2012 issue of the Archives of Internal Medicine.  They investigated the link between iodide contrast agents, commonly used in CT scans, and an increased [...]]]></description>
			<content:encoded><![CDATA[<p>Steven Brunelli, MD, MSCE, and colleagues from Harvard Medical School and Brigham and Women&#8217;s Hospital were featured in the New York times for their latest research, published in the January 23rd, 2012 issue of the Archives of Internal Medicine.  They investigated the link between iodide contrast agents, commonly used in CT scans, and an increased risk of thyroid disease.</p>
<p><a href="http://well.blogs.nytimes.com/2012/01/23/iodide-heart-scans-linked-to-thyroid-disease/" target="_blank">Iodide Heart Scans Linked to Thyroid Disease (New York Times)</a></p>
<p><a href="http://archinte.ama-assn.org/cgi/content/short/172/2/153" target="_blank">Association Between Iodinated Contrast Media Exposure and Incident Hyperthyroidism and Hypothyroidism (Archives of Internal Medicine) </a></p>
]]></content:encoded>
			<wfw:commentRss>http://www.drugepi.org/recently-at-dope/brunelli-iodide-thyroid/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>DEcIDE Methods Center CER Scan (January 2012)</title>
		<link>http://www.drugepi.org/recently-at-dope/decide-methods-center-cer-scan-january-2012/</link>
		<comments>http://www.drugepi.org/recently-at-dope/decide-methods-center-cer-scan-january-2012/#comments</comments>
		<pubDate>Tue, 10 Jan 2012 15:36:11 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[DEcIDE CER Scans]]></category>

		<guid isPermaLink="false">http://www.drugepi.org/?p=1491</guid>
		<description><![CDATA[<p>The DEcIDE Methods Center publishes a monthly literature scan of current articles of interest to the field of comparative effectiveness research.</p> <p>You can find them all <a href="./?p=1197">here</a>.</p> <p> January 2012 </p> <p>CER Scan [Epub ahead of print]</p> Pharmacoepidemiol Drug Saf. 2011 Dec 8. doi: 10.1002/pds.2256. [Epub ahead of print] <p>Applying propensity scores estimated in [...]]]></description>
			<content:encoded><![CDATA[<p>The DEcIDE Methods Center publishes a monthly literature scan of current articles of interest to the field of comparative effectiveness research.</p>
<p>You can find them all <a href="./?p=1197">here</a>.</p>
<p>
<h4 style="margin-top: 25px;">January 2012</h4>
</p>
<p><strong><u>CER Scan [Epub ahead of print]</u></strong></p>
<ol>
<li>Pharmacoepidemiol  Drug Saf. 2011 Dec 8. doi: 10.1002/pds.2256. [Epub ahead of print]</li>
<p><strong>Applying propensity scores  estimated in a full cohort to adjust for confounding in subgroup analyses. </strong>Rassen JA, Glynn RJ, Rothman KJ, Setoguchi  S, Schneeweiss S. <em>Division of  Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and  Women&#8217;s Hospital and Harvard Medical School, Boston, MA, USA. jrassen@post.harvard.edu.</em></p>
<p>BACKGROUND:  A correctly specified propensity score (PS) estimated in a cohort (&quot;cohort  PS&quot;) should, in expectation, remain valid in a subgroup population. <br />
  OBJECTIVE:  We sought to determine whether using a cohort PS can be validly applied to  subgroup analyses and, thus, add efficiency to studies with many subgroups or  restricted data. METHODS: In each of three cohort studies, we estimated a  cohort PS, defined five subgroups, and then estimated subgroup-specific PSs. We  compared difference in treatment effect estimates for subgroup analyses  adjusted by cohort PSs versus subgroup-specific PSs. Then, over 10 million  times, we simulated a population with known characteristics of confounding,  subgroup size, treatment interactions, and treatment effect and again assessed  difference in point estimates. RESULTS: We observed that point estimates in  most subgroups were substantially similar with the two methods of adjustment.  In simulations, the effect estimates differed by a median of 3.4% (interquartile  (IQ) range 1.3-10.0%). The IQ range exceeded 10% only in cases where the  subgroup had &lt;&#8201;1000 patients or few outcome events. CONCLUSIONS: Our empirical  and simulation results indicated that using a cohort PS in subgroup analyses  was a feasible approach, particularly in larger subgroups. Copyright &copy; 2011  John Wiley &amp; Sons, Ltd. <br />
  PMID: 22162077&nbsp; [PubMed - as supplied by publisher]</p>
<li>Stat  Methods Med Res. 2011 Nov 8. [Epub ahead of print]</li>
<p><strong>Extension of the modified  Poisson regression model to prospective studies with correlated binary data. </strong>Zou GY, Donner A. <em>Department of Epidemiology &amp; Biostatistics, and Robarts Clinical  Trials of Robarts Research Institute, Schulich School of Medicine &amp;  Dentistry, Canada.</em></p>
<p>The Poisson  regression model using a sandwich variance estimator has become a viable  alternative to the logistic regression model for the analysis of prospective  studies with independent binary outcomes. The primary advantage of this  approach is that it readily provides covariate-adjusted risk ratios and associated  standard errors. In this article, the model is extended to studies with  correlated binary outcomes as arise in longitudinal or cluster randomization studies.  The key step involves a cluster-level grouping strategy for the computation of  the middle term in the sandwich estimator. For a single binary exposure variable  without covariate adjustment, this approach results in risk ratio estimates and  standard errors that are identical to those found in the survey sampling  literature. Simulation results suggest that it is reliable for studies with  correlated binary data, provided the total number of clusters is at least 50.  Data from observational and cluster randomized studies are used to illustrate  the methods.<br />
  PMID: 22072596&nbsp; [PubMed - as supplied by publisher]</p>
<li>J  Clin Psychopharmacol. 2011 Dec 22. [Epub ahead of print]</li>
<p><strong>Treating Depression After  Initial Treatment Failure: Directly Comparing Switch and Augmenting Strategies  in STAR*D.</strong> Gaynes BN,  Dusetzina SB, Ellis AR, Hansen RA, Farley JF, Miller WC, St&uuml;rmer T. <em>Department of Psychiatry, School of  Medicine, UNC at Chapel Hill, Chapel Hill, NC; Department of Health Care  Policy, Harvard Medical School, Boston, MA; Harrison School of Pharmacy, Auburn  University, Auburn, AL; Division of Pharmaceutical Outcomes and Policy,  Eshelman School of Pharmacy, and Department of Epidemiology, Gillings School of  Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill,  NC.</em></p>
<p>OBJECTIVE:  Augmenting and switching antidepressant medications are the 2 most common  next-step strategies for depressed patients failing initial medication treatment.  These approaches have not been directly compared; thus, our objectives are to  compare outcomes for medication augmentation versus switching for patients with  major depressive disorder in the Sequenced Treatment Alternatives to Relieve Depression  (STAR*D) clinical trial. METHODS: We conducted a retrospective analysis of  participants aged 18 to 75 years with DSM-IV nonpsychotic depression who failed  to remit with initial treatment in the STAR*D clinical trial (N =1292). We  compared depressive symptom remission, response, and quality of life among  participants in each study arm using propensity score matching to minimize  selection bias. RESULTS: The propensity-score-matched augment (N = 269) and switch  (N = 269) groups were well balanced on measured characteristics. Neither the  likelihood of remission (risk ratio, 1.14; 95% confidence level, 0.82-1.58) or  response (risk ratio, 1.14; 95% confidence level, 0.82-1.58), nor the time to  remission (log-rank test, P = 0.946) or response (log-rank test, P = 0.243) differed  by treatment strategy. Similarly, quality of life did not differ. Post hoc  analyses suggested that augmentation improved outcomes for patients tolerating  12 or more weeks of initial treatment and those with partial initial treatment  response. CONCLUSIONS: For patients receiving and tolerating aggressive initial  antidepressant trials, there is no clear preference for next-step augmentation  versus switching. Findings tentatively suggest that those who complete an  initial treatment of 12 weeks or more and have a partial response with residual  mild depressive severity may benefit more from augmentation relative to  switching.<br />
  PMID: 22198447&nbsp; [PubMed - as supplied by publisher]</p>
<li>J  Clin Psychopharmacol. 2011 Dec 22. [Epub ahead of print]</li>
<p><strong>Variation in Antipsychotic  Treatment Choice Across US Nursing Homes. </strong>Huybrechts KF, Rothman KJ, Brookhart MA, Silliman RA, Crystal S,  Gerhard T, Schneeweiss S. <em>Division of  Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and  Women&#8217;s Hospital and Harvard Medical School; Department of Epidemiology, Boston  University School of Public Health, Boston, MA; RTI Health Solutions, Research  Triangle Park; UNC, Gillings School of Global Public Health, Chapel Hill, NC;  Department of Medicine, Boston University School of Medicine, Boston, MA; and  Rutgers University, New Brunswick, NJ.</em></p>
<p>OBJECTIVE:  Despite serious safety concerns, antipsychotic medications continue to be used  widely in US nursing homes. The objective of this study was to quantify the  variation in antipsychotic treatment choice across US nursing homes, and to characterize  its correlates. <br />
  METHODS:  Prescribing practices were assessed in a cohort of 65,618 patients 65 years or  older in 45 states who initiated treatment with an antipsychotic medication  after nursing home admission between 2001 and 2005, using merged Medicaid;  Medicare; Minimum Data Set; and Online Survey, Certification, and Reporting  data. We fit mixed-effects logistic regression models to examine how  antipsychotic treatment choice at the patient-level depends on patient and  nursing home fixed and random effects. RESULTS: Among antipsychotic medication  users, 9% of patients initiated treatment with a conventional agent. After  adjustment for case-mix and facility characteristics, 95% of nursing homes had  a predicted conventional antipsychotic prescribing rate between 2% and 20%.  Individually, patient characteristics accounted for 36% of the explained  variation, facility characteristics for 23%, and nursing home prescribing  tendency for 81%. Results were consistent in the subgroup of nursing home  patients with a diagnosis of dementia. The prescribing physician was not considered  as a determinant of treatment choice owing to data limitations. <br />
  CONCLUSION:  These findings indicate that antipsychotic treatment choice is to some extent  influenced by a nursing home&#8217;s underling prescribing &quot;culture.&quot; This  culture may reveal strategies for targeting quality improvement interventions.  In addition, these findings suggest that a nursing home&#8217;s tendency for specific  antipsychotics merits further exploration as an instrumental variable for improved  confounding adjustment in comparative effectiveness studies.<br />
  PMID: 22198446&nbsp; [PubMed - as supplied by publisher]</p>
<li>Stat  Med. 2011 Dec 4. doi: 10.1002/sim.4413. [Epub ahead of print] </li>
<p><strong>Diagnosing imputation models  by applying target analyses to posterior replicates of completed data. </strong>He Y, Zaslavsky AM.<em> Department of Health Care Policy, Harvard Medical School, Boston, MA,  02115, USA. he@hcp.med.harvard.edu.</em></p>
<p>Multiple  imputation &#64257;lls in missing data with posterior predictive draws from imputation  models. To assess the adequacy of imputation models, we can compare completed  data with their replicates simulated under the imputation model. We apply  analyses of substantive interest to both datasets and use posterior predictive  checks of the differences of these estimates to quantify the evidence of model  inadequacy. We can further integrate out the imputed missing data and their  replicates over the completed-data analyses to reduce variance in the comparison.  In many cases, the checking procedure can be easily implemented using standard  imputation software by treating re-imputations under the model as posterior  predictive replicates. Thus, it can be applied for non-Bayesian imputation  methods. We also sketch several strategies for applying the method in the  context of practical imputation analyses. We illustrate the method using two  real data applications and study its property using a simulation. Copyright &copy; 2011  John Wiley &amp; Sons, Ltd.<br />
  PMID: 22139814&nbsp; [PubMed - as supplied by publisher]</p>
</ol>
<p><strong><u>CER Scan [published within the last 30 days]</u></strong></p>
<ol>
<li>Epidemiology. 2012 Jan;23(1):151-8. </li>
<p><strong>Is probabilistic bias analysis approximately bayesian? </strong>Maclehose  RF, Gustafson P. From the <em>Divisions of  Biostatistics, and Epidemiology and Community Health, University of Minnesota,  Minneapolis, MN; and Department of Statistics, University of British Columbia,  Vancouver, British Columbia, Canada.</em></p>
<p>Case-control studies are particularly  susceptible to differential exposure misclassification when exposure status is  determined following incident case status. Probabilistic bias analysis methods  have been developed as ways to adjust standard effect estimates based on the  sensitivity and specificity of exposure misclassification. The iterative  sampling method advocated in probabilistic bias analysis bears a distinct  resemblance to a Bayesian adjustment; however, it is not identical.  Furthermore, without a formal theoretical framework (Bayesian or frequentist), the  results of a probabilistic bias analysis remain somewhat difficult to  interpret. We describe, both theoretically and empirically, the extent to which  probabilistic bias analysis can be viewed as approximately Bayesian. Although  the differences between probabilistic bias analysis and Bayesian approaches to  misclassification can be substantial, these situations often involve  unrealistic prior specifications and are relatively easy to detect. Outside of  these special cases, probabilistic bias analysis and Bayesian approaches to  exposure misclassification in case-control studies appear to perform equally  well.<br />
  PMID: 22157311&nbsp; [PubMed - in  process]</p>
<li>BMC  Med Inform Decis Mak. 2011 Dec 14;11(1):75. [Epub ahead of print] </li>
<p><strong>Evaluation of an automated  safety surveillance system using risk adjusted Sequential Probability Ratio  Testing. </strong>Matheny ME,  Normand SL, Gross TP, Marinac-Dabic D, Loyo-Berrios N, Vidi VD, Donnelly S,  Resnic FS.</p>
<p>BACKGROUND:  Automated adverse outcome surveillance tools and methods have potential utility  in quality improvement and medical product surveillance activities. Their use  for assessing hospital performance on the basis of patient outcomes has  received little attention. We compared risk-adjusted sequential probability  ratio testing (RA-SPRT) implemented in an automated tool to Massachusetts  public reports of 30-day mortality after isolated coronary artery bypass graft  surgery. METHODS: A total of 23,020 isolated adult coronary artery bypass  surgery admissions performed in Massachusetts hospitals between January 1, 2002  and September 30, 2007 were retrospectively re-evaluated. The RA-SPRT method  was implemented within an automated surveillance tool to identify hospital  outliers in yearly increments. We used an overall type I error rate of 0.05, an  overall type II error rate of 0.10, and a threshold that signaled if the odds  of dying 30-days after surgery was at least twice than expected. Annual  hospital outlier status, based on the state-reported classification, was  considered the gold standard. An event was defined as at least one occurrence  of a higher-than-expected hospital mortality rate during a given year. RESULTS:  We examined a total of 83 hospital-year observations. The RA-SPRT method  alerted 6 events among three hospitals for 30-day mortality compared with 5  events among two hospitals using the state public reports, yielding a  sensitivity of 100% (5/5) and specificity of 98.8% (79/80). CONCLUSIONS: The  automated RA-SPRT method performed well, detecting all of the true  institutional outliers with a small false positive alerting rate. Such a system  could provide confidential automated notification to local institutions in  advance of public reporting providing opportunities for earlier quality  improvement interventions. <br />
  PMID: 22168892&nbsp; [PubMed - as supplied by publisher]</p>
<p>Free Full Text: <a href="http://www.biomedcentral.com/content/pdf/1472-6947-11-75.pdf">http://www.biomedcentral.com/content/pdf/1472-6947-11-75.pdf</a></p>
<li>Stat Med. 2011 Dec 20;30(29):3447-60. doi:  10.1002/sim.4355.</li>
<p><strong>Gaussian-based routines to impute categorical variables in health  surveys.</strong> Yucel RM, He Y, Zaslavsky AM. <em>Department  of Epidemiology and Biostatistics, School of Public Health, University at  Albany, SUNY, One University Place, Rensselaer, NY 12144-3456, USA. ryucel@albany.edu</em></p>
<p>The multivariate normal (MVN)  distribution is arguably the most popular parametric model used in imputation  and is available in most software packages (e.g., SAS PROC MI, R package norm).  When it is applied to categorical variables as an approximation, practitioners  often either apply simple rounding techniques for ordinal variables or create a  distinct &#8216;missing&#8217; category and/or disregard the nominal variable from the  imputation phase. All of these practices can potentially lead to biased and/or  uninterpretable inferences. In this work, we develop a new rounding methodology  calibrated to preserve observed distributions to multiply impute missing  categorical covariates. The major attractiveness of this method is its  flexibility to use any &#8216;working&#8217; imputation software, particularly those based  on MVN, allowing practitioners to obtain usable imputations with small biases.  A simulation study demonstrates the clear advantage of the proposed method in  rounding ordinal variables and, in some scenarios, its plausibility in imputing  nominal variables. We illustrate our methods on a widely used National Survey  of Children with Special Health Care Needs where incomplete values on race  posed a valid threat on inferences pertaining to disparities. Copyright &copy; 2011  John Wiley &amp; Sons, Ltd.<br />
  PMID: 21976366&nbsp; [PubMed - in  process]</p>
</ol>
<p><strong><u>JANUARY THEME: Applications  of MSMs for Dealing with Time-varying Exposure</u></strong></p>
<ol>
<li>Int J Biostat. 2011;7(1):Article 34. Epub 2011  Sep 8. </li>
<p><strong>Antihypertensive medication use and change in kidney function in  elderly adults: a marginal structural model analysis. </strong>Odden MC, Tager IB,  van der Laan MJ, Delaney JA, Peralta CA, Katz R, Sarnak MJ, Psaty BM, Shlipak  MG. <em>Oregon State University, USA.</em></p>
<p>BACKGROUND: The evidence for the  effectiveness of antihypertensive medication use for slowing decline in kidney  function in older persons is sparse. We addressed this research question by the  application of novel methods in a marginal structural model.<br />
  METHODS: Change in kidney function was  measured by two or more measures of cystatin C in 1,576 hypertensive  participants in the Cardiovascular Health Study over 7 years of follow-up  (1989-1997 in four U.S. communities). The exposure of interest was  antihypertensive medication use. We used a novel estimator in a marginal  structural model to account for bias due to confounding and informative  censoring.<br />
  RESULTS: The mean annual decline in eGFR  was 2.41 &plusmn; 4.91 mL/min/1.73 m(2). In unadjusted analysis, antihypertensive  medication use was not associated with annual change in kidney function.  Traditional multivariable regression did not substantially change these  estimates. Based on a marginal structural analysis, persons on  antihypertensives had slower declines in kidney function; participants had an  estimated 0.88 (0.13, 1.63) ml/min/1.73 m(2) per year slower decline in eGFR  compared with persons on no treatment. In a model that also accounted for bias  due to informative censoring, the estimate for the treatment effect was 2.23<br />
  (-0.13, 4.59) ml/min/1.73 m(2) per year  slower decline in eGFR. <br />
  CONCLUSION: In summary, estimates from a  marginal structural model suggested that antihypertensive therapy was  associated with preserved kidney function in hypertensive elderly adults.  Confirmatory studies may provide power to determine the strength and validity  of the findings.<br />
  PMCID: PMC3204667 [Available on  2012/9/8]<br />
  PMID: 22049266&nbsp; [PubMed - in process]</p>
<li>Epidemiology. 2011 Nov;22(6):877-8.</li>
<p><strong>Hormonal contraception and HIV risk: evaluating  marginal-structural-model assumptions. </strong>Chen PL, Cole SR, Morrison CS. </p>
<p>Letter to the editor</p>
<p>PMID: 21968782&nbsp; [PubMed - in  process]</p>
<li>Pharmacoepidemiol  Drug Saf. 2011 Jul 22. doi: 10.1002/pds.2175. [Epub ahead of print] <strong>Comparative effectiveness of individual  angiotensin receptor blockers on risk of mortality in patients with chronic  heart failure. </strong>Desai RJ, Ashton CM, Deswal A, Morgan RO, Mehta HB, Chen H,  Aparasu RR, Johnson ML. <em>Eshelman School  of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.</em></li>
<p>&nbsp;</p>
<p>OBJECTIVE: There is little evidence on  comparative effectiveness of individual angiotensin receptor blockers (ARBs) in  patients with chronic heart failure (CHF). This study compared four ARBs in  reducing risk of mortality in clinical practice. METHODS: A retrospective  analysis was conducted on a national sample of patients diagnosed with CHF from  1 October 1996 to 30 September 2002 identified from Veterans Affairs electronic  medical records, with supplemental clinical data obtained from chart review.  After excluding patients with exposure to ARBs within the previous  6&#8201;months, four treatment groups were defined based on initial use of candesartan,  valsartan, losartan, and irbesartan between the index date (1 October 2000) and  the study end date (30 September 2002). Time to death was measured concurrently  during that period. A marginal structural model controlled for sociodemographic  factors, comorbidities, comedications, disease severity (left ventricular  ejection fraction), and potential time-varying confounding affected by previous  treatment (hospitalization). Propensity scores derived from a multinomial  logistic regression were used as inverse probability of treatment weights in a  generalized estimating equation to estimate causal effects. RESULTS: Among the 1536  patients identified on ARB therapy, irbesartan was most frequently used  (55.21%), followed by losartan (21.74%), candesartan (15.23%), and valsartan (7.81%).  When compared with losartan, after adjusting for time-varying hospitalization  in marginal structural model, candesartan (OR&#8201;=&#8201;0.79, 95%CI&#8201;=&#8201;0.42-1.50),  irbesartan (OR&#8201;=&#8201;1.17, 95%CI&#8201;=&#8201;0.72-1.90), and  valsartan (OR&#8201;=&#8201;0.98, 95%CI&#8201;=&#8201;0.45-2.14) were found to  have similar effectiveness in reducing mortality in CHF patients. CONCLUSION:  Effectiveness of ARBs in reducing mortality is similar in patients with CHF in  everyday clinical practice. Copyright &copy; 2011 John Wiley &amp; Sons, Ltd.<br />
  PMID: 21786364&nbsp; [PubMed - as  supplied by publisher]</p>
<li>Clin Trials. 2011 Jun;8(3):277-87. doi:  10.1177/1740774511402526. </li>
<p><strong>How to use marginal structural models in randomized trials to estimate  the natural direct and indirect effects of therapies mediated by causal intermediates. </strong>Oba K, Sato T, Ogihara T, Saruta T, Nakao K. Translational Research and  Clinical Trial Center, Hokkaido University Hospital, Hokkaido University, Japan.  k.oba@huhp.hokudai.ac.jp</p>
<p>Erratum in<br />
  &nbsp;&nbsp;&nbsp; Clin Trials. 2011;8(5):680.</p>
<p>BACKGROUND: Although intention-to-treat  analysis is a standard approach, additional supplemental analyses are often  required to evaluate the biological relationship among interventions,  intermediates, and outcomes. Therefore, we need to evaluate whether the effect  of an intervention on a particular outcome is mediated by a hypothesized  intermediate variable.<br />
  PURPOSE: To evaluate the size of the  direct effect in the total effect, we applied the marginal structural model to  estimate the average natural direct and indirect effects in a large-scale  randomized controlled trial (RCT). Method The average natural direct effect is  defined as the difference in the probability of a counterfactual outcome  between the experimental and control arms, with the intermediate set to what it  would have been, had the intervention been a control treatment. We considered  two marginal structural models to estimate the average natural direct and  indirect effects introduced by VanderWeele (Epidemiology 2009) and applied them  in a large-scale RCT &#8211; the Candesartan Antihypertensive Survival<br />
  Evaluation in Japan (CASE-J trial) &#8211;  that compared angiotensin receptor blockers and calcium-channel blockers in  high-risk hypertensive patients. <br />
  RESULTS: There were no strong blood  pressure-independent or dependent effects; however, a systolic blood pressure  reduction of about 1.9 &#8201;mmHg suppressed all events. Compared to the blood  pressure-independent effects of calcium channel blockers, those of angiotensin  receptor blockers contributed positively to cardiovascular and cardiac events,  but negatively to cerebrovascular events.<br />
  LIMITATIONS: There is a particular  condition for estimating the average natural direct effect. It is impossible to  check whether this condition is satisfied with the available data.<br />
  CONCLUSION: We estimated the average  natural direct and indirect effects through the achieved systolic blood  pressure in the CASE-J trial. This first application of estimating the average  natural effects in an RCT can be useful for obtaining an in-depth understanding  of the results and further development of similar interventions.<br />
  PMID: 21730076&nbsp; [PubMed - indexed  for MEDLINE]</p>
<li>J Consult Clin Psychol. 2011 Apr;79(2):225-35. <strong>A marginal structural model analysis for  loneliness: implications for intervention trials and clinical practice.</strong> VanderWeele  TJ, Hawkley LC, Thisted RA, Cacioppo JT. <em>Harvard  University, Department of Epidemiology, Harvard School of Public Health, 677  Huntington Avenue, Boston, MA 02115, USA. tvanderw@hsph.harvard.edu</em></li>
<p>&nbsp;</p>
<p>OBJECTIVE: Clinical scientists,  policymakers, and individuals must make decisions concerning effective  interventions that address health-related issues. We use longitudinal data on  loneliness and depressive symptoms and a new class of causal models to  illustrate how empirical evidence can be used to inform intervention trial  design and clinical practice.<br />
  METHOD: Data were obtained from a  population-based study of non-Hispanic Caucasians, African Americans, and  Latino Americans (N = 229) born between 1935 and 1952. Loneliness and  depressive symptoms were measured with the UCLA Loneliness Scale-Revised and  Center for Epidemiologic Studies Depression Scale, respectively. Marginal  structural causal models were employed to evaluate the extent to which  depressive symptoms depend not only on loneliness measured at a single point in  time (as in prior studies of the effect of loneliness) but also on an  individual&#8217;s entire loneliness history.<br />
  RESULTS: Our results indicate that if  interventions to reduce loneliness by 1 standard deviation were made 1 and 2  years prior to assessing depressive symptoms, both would have an effect;  together, they would result in an average reduction in depressive symptoms of  0.33 standard deviations, 95% CI [0.21,<br />
  0.44], p &lt; .0001. <br />
  CONCLUSIONS: The magnitude and  persistence of these effects suggest that greater effort should be devoted to  developing practical interventions on alleviating loneliness and that doing so  could be useful in the treatment and prevention of depressive symptoms. In  light of the persistence of the effects of loneliness, our results also suggest  that, in the evaluation of interventions on loneliness, it may be important to  allow for a considerable follow-up period in assessing outcomes.<br />
  (c) 2011 APA, all rights reserved. <br />
  PMCID: PMC3079447 [Available on 2012/4/1]<br />
  PMID: 21443322&nbsp; [PubMed - indexed  for MEDLINE]</p>
<li>J Clin Psychopharmacol. 2011 Apr;31(2):226-30. </li>
<p><strong>Differential 3-year effects of first- versus second-generation  antipsychotics on subjective well-being in schizophrenia using marginal  structural models. </strong>Lambert M, Schimmelmann BG, Schacht A, Suarez D, Haro  JM, Novick D, Wagner T, Wehmeier PM, Huber CG, Hundemer HP, Dittmann RW, Naber  D. <em>Psychosis Centre, Department of  Psychiatry and Psychotherapy, Centre for Psychosocial Medicine, University  Medical Centre Hamburg-Eppendorf, Germany. </em></p>
<p>OBJECTIVE: This study examined the  differential effects of first- (FGAs) versus second-generation antipsychotics  (SGAs) on subjective well-being in patients with schizophrenia.<br />
  METHOD: Data were collected in an  observational 3-year follow-up study of 2224 patients with schizophrenia.  Subjective well-being was assessed with the Subjective Well-being under  Neuroleptic Treatment Scale (SWN-K). Differential effects of FGAs versus SGAs  were analyzed using marginal structural models in those patients taking  antipsychotic monotherapy.<br />
  RESULTS: The marginal structural model,  which analyzed the differential effect on the SWN-K total score, revealed that  patients on SGAs had significantly higher SWN-K total scores, starting at 6  months (3.02 points; P = 0.0061, d = 0.20) and remaining significant thereafter  (end point: 5.35 points; P = 0.0074, d = 0.36).<br />
  CONCLUSIONS: Results of this large  observational study are consistent with a small but clinically relevant  superiority of SGAs over FGAs in subjective well-being extending previous  positive findings of differential effects on quality of life.<br />
  PMID: 21346606&nbsp; [PubMed - indexed  for MEDLINE]</p>
<li>Arch Intern Med. 2011 Jan 24;171(2):110-8. Epub  2010 Sep 27. </li>
<p><strong>Similar outcomes with hemodialysis and peritoneal dialysis in patients  with end-stage renal disease.</strong> Mehrotra R, Chiu YW, Kalantar-Zadeh K,  Bargman J, Vonesh E. Los Angeles Biomedical Research Institute at Harbor-UCLA  Medical Center, Torrance, CA 90502, USA. rmehrotra@labiomed.org </p>
<p>Comment in<br />
  &nbsp;&nbsp;&nbsp; Arch Intern Med. 2011 Jan 24;171(2):107-9.</p>
<p>BACKGROUND: The annual payer costs for  patients treated with peritoneal dialysis (PD) are lower than with hemodialysis  (HD), but in 2007, only 7% of dialysis patients in the United States were  treated with PD. Since 1996, there has been no change in the first-year  mortality of HD patients, but both short- and long-term outcomes of PD patients  have improved.<br />
  METHODS: Data from the US Renal Data  System were examined for secular trends in survival among patients treated with  HD and PD on day 90 of end-stage renal disease (HD, 620 020 patients; PD, 64  406 patients) in three 3-year cohorts (1996-1998, 1999-2001, and 2002-2004) for  up to 5 years of follow-up using a nonproportional hazards marginal structural  model with inverse probability of treatment and censoring weighting. <br />
  RESULTS: There was a progressive  attenuation in the higher risk for death seen in patients treated with PD in  earlier cohorts; for the 2002-2004 cohort, there was no significant difference  in the risk of death for HD and PD patients through 5 years of follow-up. The  median life expectancy of HD and PD patients was 38.4 and 36.6 months, respectively.  Analyses in 8 subgroups based on age (&lt;65 and &#8805;65 years), diabetic  status, and baseline comorbidity (none and &#8805;1) showed greater improvement  in survival among patients treated with PD relative to HD at all follow-up  periods.<br />
  CONCLUSION: In the most recent cohorts,  patients who began treatment with HD or PD have similar outcomes. <br />
  PMID: 20876398&nbsp; [PubMed - indexed  for MEDLINE]</p>
<li>Epidemiology. 2010 Jul;21(4):528-39. </li>
<p><strong>Estimating absolute risks in the presence of nonadherence: an  application to a follow-up study with baseline randomization. </strong>Toh S,  Hern&aacute;ndez-D&iacute;az S, Logan R, Robins JM, Hern&aacute;n MA. Department of Epidemiology,  Harvard School of Public Health, Boston, MA 02215</p>
<p>The intention-to-treat (ITT) analysis  provides a valid test of the null hypothesis and naturally results in both  absolute and relative measures of risk. However, this analytic approach may  miss the occurrence of serious adverse effects that would have been detected  under full adherence to the assigned treatment. Inverse probability weighting  of marginal structural models has been used to adjust for nonadherence, but  most studies have provided only relative measures of risk. In this study, we  used inverse probability weighting to estimate both absolute and relative  measures of risk of invasive breast cancer under full adherence to the assigned  treatment in the Women&#8217;s Health Initiative estrogen-plus-progestin trial. In  contrast to an ITT hazard ratio (HR) of 1.25 (95% confidence interval [CI] =  1.01 to 1.54), the HR for 8-year continuous estrogen-plus-progestin use versus  no use was 1.68 (1.24 to 2.28). The estimated risk difference (cases/100 women)  at year 8 was 0.83 (-0.03 to 1.69) in the ITT analysis, compared with 1.44  (0.52 to 2.37) in the adherence-adjusted analysis. Results were robust across  various dose-response models. We also compared the dynamic treatment regimen  &quot;take hormone therapy until certain adverse events become apparent, then  stop taking hormone therapy&quot; with no use (HR = 1.64; 95% CI<br />
  = 1.24 to 2.18). The methods described  here are also applicable to observational studies with time-varying treatments. <br />
  PMID: 20526200&nbsp; [PubMed - indexed  for MEDLINE]</p>
<li>Lifetime Data Anal. 2010 Jan;16(1):71-84. Epub  2009 Nov 6. </li>
<p><strong>Relation between three classes of structural models for the effect of a  time-varying exposure on survival.</strong> Young JG, Hern&aacute;n MA, Picciotto S, Robins  JM. Department of Epidemiology, Harvard School of Public Health, 677 Huntington  Avenue, Kresge Bldg Suite 820, Boston, MA 02115, USA. jyoung@hsph.harvard.edu</p>
<p>Standard methods for estimating the  effect of a time-varying exposure on survival may be biased in the presence of  time-dependent confounders themselves affected by prior exposure. This problem  can be overcome by inverse probability weighted estimation of Marginal Structural  Cox Models (Cox MSM), g-estimation of Structural Nested Accelerated Failure  Time Models (SNAFTM) and g-estimation of<br />
  Structural Nested Cumulative Failure  Time Models (SNCFTM). In this paper, we describe a data generation mechanism  that approximately satisfies a Cox MSM, an SNAFTM and an SNCFTM. Besides  providing a procedure for data simulation, our formal description of a data  generation mechanism that satisfies all three models allows one to assess the  relative advantages and disadvantages of each modeling approach. A simulation  study is also presented to compare effect estimates across the three models.<br />
  PMID: 19894116&nbsp; [PubMed - indexed  for MEDLINE]</p>
<li>J Rheumatol. 2009 Mar;36(3):560-4. Epub 2009 Feb  4. </li>
<p><strong>Prednisone, lupus activity, and permanent organ damage.</strong> Thamer M,  Hern&aacute;n MA, Zhang Y, Cotter D, Petri M. Medical Technology and Practice Patterns  Institute, Bethesda, MD 20814</p>
<p>OBJECTIVE: To estimate the effect of  corticosteroids (prednisone dose) on permanent organ damage among persons with  systemic lupus erythematosus (SLE). METHODS: We identified 525 patients with  incident SLE in the Hopkins Lupus Cohort. At each visit, clinical activity  indices, laboratory data, and treatment were recorded. The study population was  followed from the month after the first visit until June 29, 2006, or  attainment of irreversible organ damage, death, loss to follow-up, or receipt  of pulse methylprednisolone therapy. We estimated the effect of cumulative  average dose of prednisone on organ damage using a marginal structural model to  adjust for time-dependent confounding by indication due to SLE disease  activity.<br />
  RESULTS: Compared with non-prednisone  use, the hazard ratio of organ damage for prednisone was 1.16 (95% CI 0.54,  2.50) for cumulative average doses &gt; 0-180 mg/month, 1.50 (95% CI 0.58,  3.88) for &gt; 180-360 mg/month, 1.64 (95% CI 0.58, 4.69) for &gt; 360-540  mg/month, and 2.51 (95% CI 0.87, 7.27) for &gt; 540 mg/month. In contrast,  standard Cox regression models estimated higher hazard ratios at all dose  levels.<br />
  CONCLUSION: Our results suggest that low  doses of prednisone do not result in a substantially increased risk of  irreversible organ damage. <br />
  PMID: 19208608&nbsp; [PubMed - indexed  for MEDLINE]</p>
</ol>
]]></content:encoded>
			<wfw:commentRss>http://www.drugepi.org/recently-at-dope/decide-methods-center-cer-scan-january-2012/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Steven Brunelli Receives Mentor Award</title>
		<link>http://www.drugepi.org/recently-at-dope/steven-brunelli-receives-mentor-award/</link>
		<comments>http://www.drugepi.org/recently-at-dope/steven-brunelli-receives-mentor-award/#comments</comments>
		<pubDate>Tue, 03 Jan 2012 20:35:25 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Faculty Accomplishments]]></category>

		<guid isPermaLink="false">http://www.drugepi.org/?p=1479</guid>
		<description><![CDATA[<p>Steven Brunelli, MD, MSCE received BWH&#8217;s 2011 Department of Medicine Early Career Mentoring Award. This award recognizes the efforts of an early career HMS faculty member in the career development of residents, fellows, and/or other faculty.</p>]]></description>
			<content:encoded><![CDATA[<p>Steven Brunelli, MD, MSCE received BWH&#8217;s 2011 Department of Medicine Early Career Mentoring Award. This award recognizes the efforts of an early career HMS faculty member in the career development of residents, fellows, and/or other faculty.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.drugepi.org/recently-at-dope/steven-brunelli-receives-mentor-award/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Aaron Kesselheim Profiled in the December Issue of Health Affairs</title>
		<link>http://www.drugepi.org/recently-at-dope/askhealthaffairs/</link>
		<comments>http://www.drugepi.org/recently-at-dope/askhealthaffairs/#comments</comments>
		<pubDate>Wed, 14 Dec 2011 20:28:09 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Faculty Accomplishments]]></category>
		<category><![CDATA[Faculty in the Media]]></category>

		<guid isPermaLink="false">http://www.drugepi.org/?p=1445</guid>
		<description><![CDATA[<p>Aaron Kesselheim, MD, JD, MPH, is the subject of a special feature in the December 2011 issue of the journal Health Affairs.  In it, Dr. Kesselheim discusses how he combines his expertise as a general internist, patent attorney, and health services researcher to better serve his patients. Dr. Kesselheim also is an author of 2 [...]]]></description>
			<content:encoded><![CDATA[<p>Aaron Kesselheim, MD, JD, MPH, is the subject of a special feature in the December 2011 issue of the journal Health Affairs.  In it, Dr. Kesselheim discusses how he combines his expertise as a general internist, patent attorney, and health services researcher to better serve his patients.  Dr. Kesselheim also is an author of 2 articles in the December issue.</p>
<p><a href="http://content.healthaffairs.org/content/30/12/2328.full.html" target="_blank">Understanding How ‘The System’ Can Be Made To Work Better For Patients</a></p>
]]></content:encoded>
			<wfw:commentRss>http://www.drugepi.org/recently-at-dope/askhealthaffairs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Jerry Avorn on a Half-Century of Drug Safety Monitoring</title>
		<link>http://www.drugepi.org/recently-at-dope/avorndecnejm/</link>
		<comments>http://www.drugepi.org/recently-at-dope/avorndecnejm/#comments</comments>
		<pubDate>Thu, 08 Dec 2011 21:10:53 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Faculty in the Media]]></category>

		<guid isPermaLink="false">http://www.drugepi.org/?p=1398</guid>
		<description><![CDATA[<p>Jerry Avorn, MD, offers his perspective on the evolution of drug safety monitoring in the US in the December 8th, 2011 issue of the New England Journal of Medicine. In addition to his written perspective, Dr. Avorn also gave an interview with NEJM on the same topic. </p> <p><a href="http://www.nejm.org/doi/full/10.1056/NEJMp1110327" target="_blank"> Learning about the Safety [...]]]></description>
			<content:encoded><![CDATA[<p>Jerry Avorn, MD, offers his perspective on the evolution of drug safety monitoring in the US in the December 8th, 2011 issue of the New England Journal of Medicine.  In addition to his written perspective, Dr. Avorn also gave an interview with NEJM on the same topic. </p>
<p><a href="http://www.nejm.org/doi/full/10.1056/NEJMp1110327" target="_blank"> Learning about the Safety of Drugs — A Half-Century of Evolution</a></p>
]]></content:encoded>
			<wfw:commentRss>http://www.drugepi.org/recently-at-dope/avorndecnejm/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>DEcIDE Methods Center CER Scan (December 2011)</title>
		<link>http://www.drugepi.org/recently-at-dope/decide-methods-center-cer-scan-december-2011/</link>
		<comments>http://www.drugepi.org/recently-at-dope/decide-methods-center-cer-scan-december-2011/#comments</comments>
		<pubDate>Mon, 05 Dec 2011 22:54:26 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[DEcIDE CER Scans]]></category>

		<guid isPermaLink="false">http://www.drugepi.org/?p=1470</guid>
		<description><![CDATA[<p>The DEcIDE Methods Center publishes a monthly literature scan of current articles of interest to the field of comparative effectiveness research.</p> <p>You can find them all <a href="./?p=1197">here</a>.</p> December 2011 <p></a></p> <p>CER Scan [Epub ahead of print]</p> Drug Saf. 2011 Jan 2012; 35(1):61-78 [Epub ahead of print] <p> Identifying Adverse Events of Vaccines Using a [...]]]></description>
			<content:encoded><![CDATA[<p>The DEcIDE Methods Center publishes a monthly literature scan of current articles of interest to the field of comparative effectiveness research.</p>
<p>You can find them all <a href="./?p=1197">here</a>.</p>
<h4 style="margin-top: 25px;">December 2011</h4>
<p></a></p>
<p><strong><u>CER Scan [Epub ahead of print]</u></strong></p>
<ol>
<li>Drug Saf. 2011 Jan 2012; 35(1):61-78 [Epub ahead of print] </li>
<p><strong>	Identifying Adverse Events  of Vaccines Using a Bayesian Method of Medically Guided Information Sharing.</strong> Crooks CJ, Prieto-Merino D, Evans SJ. <em>Division of Epidemiology and Public Health,  University of Nottingham, Nottingham, UK.</em></p>
<p>Background:  The detection of adverse events following immunization (AEFI) fundamentally  depends on how these events are classified. Standard methods impose a choice  between either grouping similar events together to gain power or splitting them  into more specific definitions. We demonstrate a method of medically guided  Bayesian information sharing that avoids grouping or splitting the data, and we  further combine this with the standard epidemiological tools of stratification  and multivariate regression. Objective: The aim of this study was to assess the  ability of a Bayesian hierarchical model to identify gastrointestinal AEFI in  children, and then combine this with testing for effect modification and  adjustments for confounding. Study Design: Reporting odds ratios were  calculated for each gastrointestinal AEFI and vaccine combination. After testing  for effect modification, these were then re-estimated using multivariable logistic  regression adjusting for age, sex, year and country of report. A medically  guided hierarchy of AEFI terms was then derived to allow information sharing in  a Bayesian model. Setting: All spontaneous reports of AEFI in children under 18  years of age in the WHO VigiBase&trade; (Uppsala Monitoring Centre, Uppsala, Sweden)  before June 2010. Reports with missing age were included in the main analysis  in a separate category and excluded in a subsequent sensitivity analysis.  Exposures: The 15 most commonly prescribed childhood vaccinations, excluding  influenza vaccines. Main Outcome Measures: All gastrointestinal AEFI coded by  WHO Adverse Reaction Terminology. Results: A crude analysis identified 132  signals from 655 reported combinations of gastrointestinal AEFI. Adjusting for  confounding by age, sex, year of report and country of report, where appropriate,  reduced the number of signals identified to 88. The addition of a Bayesian  hierarchical model identified four further signals and removed three. Effect  modification by age and sex was identified for six vaccines for the outcomes of  vomiting, nausea, diarrhoea and salivary gland enlargement.<br />
  Conclusion:  This study demonstrated a sequence of methods for routinely analysing spontaneous  report databases that was easily understandable and reproducible. The combination  of classical and Bayesian methods in this study help to focus the limited  resources for hypothesis testing studies towards adverse events with the  strongest support from the data.<br />
  PMID:  22136183 [PubMed - as supplied by publisher]</p>
</ol>
<p><strong><u>CER Scan [published within the last 30 days]</u></strong></p>
<ol>
<li>Am J Epidemiol. 2011 Dec 1;174(11):1213-22. Epub  2011 Oct 24. </li>
<p><strong>Effects of adjusting for instrumental variables on bias and precision  of effect estimates. </strong><br />
  Myers JA, Rassen JA,  Gagne JJ, Huybrechts KF, Schneeweiss S, Rothman KJ, Joffe MM, Glynn RJ.</p>
<p>Recent theoretical studies have shown  that conditioning on an instrumental variable (IV), a variable that is  associated with exposure but not associated with outcome except through  exposure, can increase both bias and variance of exposure effect estimates.  Although these findings have obvious implications in cases of known IVs, their  meaning remains unclear in the more common scenario where investigators are  uncertain whether a measured covariate meets the criteria for an IV or rather a  confounder. The authors present results from two simulation studies designed to  provide insight into the problem of conditioning on potential IVs in routine  epidemiologic practice. The simulations explored the effects of conditioning on  IVs, near-IVs (predictors of exposure that are weakly associated with outcome),  and confounders on the bias and variance of a binary exposure effect estimate.  The results indicate that effect estimates which are conditional on a perfect  IV or near-IV may have larger bias and variance than the unconditional  estimate. However, in most scenarios considered, the increases in error due to  conditioning were small compared with the total estimation error. In these  cases, minimizing unmeasured confounding should be the priority when selecting  variables for adjustment, even at the risk of conditioning on IVs. <br />
  PMID: 22025356&nbsp; [PubMed - in process]</p>
<li>Am J Epidemiol. 2011 Dec 1;174(11):1223-7. Epub  2011 Oct 27. </li>
<p><strong>Invited commentary: understanding bias amplification.</strong> Pearl J.</p>
<p>In choosing covariates for adjustment or  inclusion in propensity score analysis, researchers must weigh the benefit of  reducing confounding bias carried by those covariates against the risk of  amplifying residual bias carried by unmeasured confounders. The latter is  characteristic of covariates that act like instrumental variables-that is,  variables that are more strongly associated with the exposure than with the  outcome. In this issue of the Journal (Am J Epidemiol. 2011;174(11):1213-1222),  Myers et al. compare the bias amplification of a near-instrumental variable  with its bias-reducing potential and suggest that, in practice, the latter  outweighs the former. The author of this commentary sheds broader light on this  comparison by considering the cumulative effects of conditioning on multiple  covariates and showing that bias amplification may build up at a faster rate  than bias reduction. The author further derives a partial order on sets of  covariates which reveals preference for conditioning on outcome-related, rather  than exposure-related, confounders.<br />
  PMCID: PMC3224255 [Available on  2012/12/1] PMID: 22034488 [PubMed - in process]</p>
<li>Am J Epidemiol. 2011 Dec 1;174(11):1228-9. Epub  2011 Oct 24. Myers et Al. Response to &quot;understanding bias  amplification&quot;. Myers JA, Rassen JA, Gagne JJ, Huybrechts KF, Schneeweiss  S, Rothman KJ, Glynn RJ.</li>
<p>&nbsp;</p>
<p>Response to Invited Commentary<br />
  PMID: 22025355&nbsp; [PubMed - in process]</p>
<li>Epidemiology. 2011 Nov;22(6):815-22.</li>
<p><strong>Estimating bias from loss to follow-up in the Danish National Birth  Cohort.</strong> Greene N, Greenland S, Olsen J, Nohr EA. <em>Department of Epidemiology, School of Public Health, University of  California</em></p>
<p>Loss to follow-up in cohort studies may  result in biased association estimates. Of 61,895 women entering the Danish  National Birth Cohort and completing the first data-collection phase, 37,178  (60%) opted to be in the 7-year follow-up. Using national registry data to  obtain end point information on all members of the cohort, we estimated  associations in the baseline and the 7-year follow-up participant populations  for 5 exposure-outcome associations: (a) size at birth and childhood asthma,  (b) assisted reproductive treatment and childhood hospitalizations, (c)  prepregnancy body mass index and childhood infections, (d) alcohol drinking in  early pregnancy and childhood developmental disorders, and (e) maternal smoking  in pregnancy and childhood attention-deficit hyperactivity disorder (ADHD). We  estimated follow-up bias in the odds or rate ratios by calculating relative  ratios. For all but one of the above analyses, the bias appeared to be small,  between -10% and +8%. For maternal smoking in pregnancy and childhood ADHD, we  estimated a positive bias of approximately 33% (95% bootstrap limits of -30%  and +152%). The presence and magnitude of bias due to loss to follow-up  depended on the nature of the factors or outcomes examined, with the most  pronounced contribution in this study coming from maternal smoking. Our methods  and results may inform bias analyses in future pregnancy cohort studies. <br />
  PMID: 21918455&nbsp; [PubMed - in process]</p>
</ol>
<p><strong><u>DECEMBER THEME</u>:  Methods for Addressing Missing Data in CER</strong></p>
<ol>
<li>Stat Med. 2011 Dec 4. doi: 10.1002/sim.4413.  [Epub ahead of print]</li>
<p><strong>Diagnosing imputation models by applying target analyses to posterior  replicates of completed data. </strong>He Y, Zaslavsky AM. <em>Department of Health Care Policy, Harvard Medical School, Boston, MA,  02115, USA. he@hcp.med.harvard.edu.</em></p>
<p>Multiple imputation &#64257;lls in  missing data with posterior predictive draws from imputation models. To assess  the adequacy of imputation models, we can compare completed data with their  replicates simulated under the imputation model. We apply analyses of  substantive interest to both datasets and use posterior predictive checks of  the differences of these estimates to quantify the evidence of model  inadequacy. We can further integrate out the imputed missing data and their  replicates over the completed-data analyses to reduce variance in the comparison.  In many cases, the checking procedure can be easily implemented using standard  imputation software by treating re-imputations under the model as posterior  predictive replicates. Thus, it can be applied for non-Bayesian imputation  methods. We also sketch several strategies for applying the method in the  context of practical imputation analyses. We illustrate the method using two  real data applications and study its property using a simulation. Copyright &copy; 2011  John Wiley &amp; Sons, Ltd. Copyright &copy; 2011 John Wiley &amp; Sons, Ltd.<br />
  PMID: 22139814&nbsp; [PubMed - as supplied by publisher]</p>
<li>Stat Methods Med Res. 2011 Mar 23. [Epub ahead  of print] </li>
<p><strong>Using causal diagrams to guide analysis in missing data problems.</strong> Daniel  RM, Kenward MG, Cousens SN, De Stavola BL. <em>Faculty  of Epidemiology and Population Health, London School of Hygiene and Tropical  Medicine, London WC1E 7HT, UK.</em></p>
<p>Estimating causal effects from  incomplete data requires additional and inherently untestable assumptions  regarding the mechanism giving rise to the missing data. We show that using  causal diagrams to represent these additional assumptions both complements and  clarifies some of the central issues in missing data theory, such as Rubin&#8217;s  classification of missingness mechanisms (as missing completely at random  (MCAR), missing at random (MAR) or missing not at random (MNAR)) and the circumstances  in which causal effects can be estimated without bias by analysing only the  subjects with complete data. In doing so, we formally extend the back-door  criterion of Pearl and others for use in incomplete data examples. These ideas  are illustrated with an example drawn from an occupational cohort study of the  effect of cosmic radiation on skin cancer incidence. <br />
  PMID: 21389091&nbsp; [PubMed - as supplied by publisher]</p>
<li>Stat Med. 2011 Mar 15;30(6):627-41. doi: 10.1002/sim.4124.  Epub 2010 Dec 28. </li>
<p><strong>Estimating propensity scores with missing covariate data using general  location mixture models. </strong>Mitra R, Reiter JP. <em>School of Mathematics, University of Southampton, Southampton, SO17  1BJ, U.K. R.Mitra@soton.ac.uk</em></p>
<p>In many observational studies, analysts  estimate causal effects using propensity scores, e.g. by matching,  sub-classifying, or inverse probability weighting based on the scores.  Estimation of propensity scores is complicated when some values of the  covariates are missing. Analysts can use multiple imputation to create completed  data sets from which propensity scores can be estimated. We propose a general  location mixture model for imputations that assumes that the control units are  a latent mixture of (i) units whose covariates are drawn from the same  distributions as the treated units&#8217; covariates and (ii) units whose covariates are  drawn from different distributions. This formulation reduces the influence of control  units outside the treated units&#8217; region of the covariate space on the estimation  of parameters in the imputation model, which can result in more plausible  imputations. In turn, this can result in more reliable estimates of propensity  scores and better balance in the true covariate distributions when matching or  sub-classifying. We illustrate the benefits of the latent class modeling  approach with simulations and with an observational study of the effect of  breast feeding on children&#8217;s cognitive abilities. Copyright &copy; 2010 John Wiley  &amp; Sons, Ltd.<br />
  PMID: 21337358&nbsp; [PubMed - indexed for MEDLINE]</p>
<li>Am J Epidemiol. 2010 Nov 1;172(9):1070-6. Epub  2010 Sep 14. </li>
<p><strong>Multiple imputation for missing data via sequential regression trees. </strong>Burgette  LF, Reiter JP. <em>Department of Statistical  Science, Duke University, Durham, North Carolina 27708.</em></p>
<p>Multiple imputation is particularly well  suited to deal with missing data in large epidemiologic studies, because  typically these studies support a wide range of analyses by many data users.  Some of these analyses may involve complex modeling, including interactions and  nonlinear relations. Identifying such relations and encoding them in imputation  models, for example, in the conditional regressions for multiple imputation via  chained equations, can be daunting tasks with large numbers of categorical and  continuous variables. The authors present a nonparametric approach for  implementing multiple imputation via chained equations by using sequential  regression trees as the conditional models. This has the potential to capture  complex relations with minimal tuning by the data imputer. Using simulations,  the authors demonstrate that the method can result in more plausible  imputations, and hence more reliable inferences, in complex settings than the  naive application of standard sequential regression imputation techniques. They  apply the approach to impute missing values in data on adverse birth outcomes  with more than 100 clinical and survey variables. They evaluate the imputations  using posterior predictive checks with several epidemiologic analyses of  interest.<br />
  PMID: 20841346&nbsp; [PubMed - indexed for MEDLINE]</p>
<p>Free Full Text: <a href="http://aje.oxfordjournals.org/content/172/9/1070.long">http://aje.oxfordjournals.org/content/172/9/1070.long</a></p>
<li>Artif Intell Med. 2010 Oct;50(2):105-15. Epub  2010 Jul 16. </li>
<p><strong>Missing data imputation using statistical and machine learning methods  in a real breast cancer problem. </strong>Jerez JM, Molina I, Garc&iacute;a-Laencina PJ,  Alba E, Ribelles N, Mart&iacute;n M, Franco L. <em>Departamento  de Lenguajes y Ciencias de la Computaci&oacute;n, Universidad de M&aacute;laga, E.T.S.I.  Inform&aacute;tica, Campus de Teatinos s/n, 29071 M&aacute;laga, Spain. jja@lcc.uma.es</em></p>
<p>OBJECTIVES: Missing data imputation is  an important task in cases where it is crucial to use all available data and  not discard records with missing values. This work evaluates the performance of  several statistical and machine learning imputation methods that were used to  predict recurrence in patients in an extensive real breast cancer data set.<br />
  MATERIALS AND METHODS: Imputation  methods based on statistical techniques, e.g., mean, hot-deck and multiple  imputation, and machine learning techniques, e.g., multi-layer perceptron  (MLP), self-organisation maps (SOM) and k-nearest neighbour (KNN), were applied  to data collected through the &quot;El &Aacute;lamo-I&quot; project, and the results  were then compared to those obtained from the listwise deletion<br />
  (LD) imputation method. The database  includes demographic, therapeutic and recurrence-survival information from 3679  women with operable invasive breast cancer diagnosed in 32 different hospitals  belonging to the Spanish Breast Cancer Research Group (GEICAM). The accuracies  of predictions on early cancer relapse were measured using artificial neural  networks (ANNs), in which different ANNs were estimated using the data sets with  imputed missing values.<br />
  RESULTS: The imputation methods based on  machine learning algorithms outperformed imputation statistical methods in the  prediction of patient outcome. Friedman&#8217;s test revealed a significant  difference (p=0.0091) in the observed area under the ROC curve (AUC) values,  and the pairwise comparison test showed that the AUCs for MLP, KNN and SOM were  significantly higher (p=0.0053, p=0.0048 and p=0.0071, respectively) than the  AUC from the LD-based prognosis model.<br />
  CONCLUSION: The methods based on machine  learning techniques were the most suited for the imputation of missing values  and led to a significant enhancement of prognosis accuracy compared to  imputation methods based on statistical procedures.<br />
  Copyright &copy; 2010 Elsevier B.V. All rights  reserved.<br />
  PMID: 20638252&nbsp; [PubMed - indexed for MEDLINE]</p>
<li>J Clin Epidemiol. 2010 Jul;63(7):728-36. Epub  2010 Mar 25. </li>
<p><strong>Unpredictable bias when using the missing indicator method or complete  case analysis for missing confounder values: an empirical example.</strong> Knol MJ,  Janssen KJ, Donders AR, Egberts AC, Heerdink ER, Grobbee DE, Moons KG, Geerlings  MI. <em>Julius Center for Health Sciences and  Primary Care, University Medical Center Utrecht, Str. 6.131, PO Box 85500, 3508  GA Utrecht, The Netherlands. m.j.knol@umcutrecht.nl</em></p>
<p>OBJECTIVE: Missing indicator method  (MIM) and complete case analysis (CC) are frequently used to handle missing  confounder data. Using empirical data, we demonstrated the degree and direction  of bias in the effect estimate when using these methods compared with multiple  imputation (MI).<br />
  STUDY DESIGN AND SETTING: From a cohort  study, we selected an exposure (marital status), outcome (depression), and  confounders (age, sex, and income). Missing values in &quot;income&quot; were  created according to different patterns of missingness: missing values were  created completely at random and depending on exposure and outcome values.  Percentages of missing values ranged from 2.5% to 30%.<br />
  RESULTS: When missing values were  completely random, MIM gave an overestimation of the odds ratio, whereas CC and  MI gave unbiased results. MIM and CC gave under- or overestimations when  missing values depended on observed values. Magnitude and direction of bias  depended on how the missing values were related to exposure and outcome. Bias  increased with increasing percentage of missing<br />
  values.<br />
  CONCLUSION: MIM should not be used in  handling missing confounder data because it gives unpredictable bias of the  odds ratio even with small percentages of missing values. CC can be used when  missing values are completely random, but it gives loss of statistical power.<br />
  Copyright 2010 Elsevier Inc. All rights  reserved.<br />
  PMID: 20346625&nbsp; [PubMed - indexed for MEDLINE]</p>
<li>Pharmacoepidemiol Drug Saf. 2010  Jun;19(6):618-26. </li>
<p><strong>Issues in multiple imputation of missing data for large general  practice clinical databases.</strong> Marston L, Carpenter JR, Walters KR, Morris  RW, Nazareth I, Petersen I. <em>Department of  Primary Care and Population Health, University College London, Rowland Hill  Street, London NW32PF</em></p>
<p>PURPOSE: Missing data are a substantial  problem in clinical databases. This paper aims to examine patterns of missing  data in a primary care database, compare this to nationally representative  datasets and explore the use of multiple imputation (MI) for these data. <br />
  METHODS: The patterns and extent of  missing health indicators in a UK primary care database (THIN) were quantified  using 488 384 patients aged 16 or over in their first year after registration  with a GP from 354 General Practices. MI models were developed and the  resulting data compared to that from nationally representative datasets (14 142  participants aged 16 or over from the Health Survey for England 2006 (HSE) and  4 252 men from the British Regional Heart Study (BRHS)).<br />
  RESULTS: Between 22% (smoking) and 38%  (height) of health indicator data were missing in newly registered patients,  2004-2006. Distributions of height, weight and blood pressure were comparable  to HSE and BRHS, but alcohol and smoking were not. After MI the percentage of  smokers and non-drinkers was higher in THIN than the comparison datasets, while  the percentage of ex-smokers and heavy drinkers was lower. Height, weight and  blood pressure remained similar to the comparison datasets.<br />
  CONCLUSIONS: Given available data, the  results are consistent with smoking and alcohol data missing not at random  whereas height, weight and blood pressure missing at random. Further research  is required on suitable imputation methods for smoking and alcohol in such  databases.<br />
  PMID: 20306452&nbsp; [PubMed - indexed for MEDLINE]</p>
<li>Circ Cardiovasc Qual Outcomes. 2010  Jan;3(1):98-105. </li>
<p><strong>Missing data analysis using multiple imputation: getting to the heart  of the matter. </strong>He Y. <em>Department of  Health Care Policy, Harvard Medical School</em></p>
<p>Missing data are a pervasive problem in  health investigations. We describe some background of missing data analysis and  criticize ad hoc methods that are prone to serious problems. We then focus on multiple  imputation, in which missing cases are first filled in by several sets of plausible  values to create multiple completed datasets, then standard complete-data  procedures are applied to each completed dataset, and finally the multiple sets  of results are combined to yield a single inference. We introduce the basic  concepts and general methodology and provide some guidance for application. For  illustration, we use a study assessing the effect of cardiovascular diseases on  hospice discussion for late stage lung cancer patients.<br />
  PMCID: PMC2818781; PMID: 20123676  [PubMed - indexed for MEDLINE]</p>
<p>Free PDF: <a href="http://circoutcomes.ahajournals.org/content/3/1/98.full.pdf+html">http://circoutcomes.ahajournals.org/content/3/1/98.full.pdf+html</a></p>
<li>Am J Epidemiol. 2010 Mar 1;171(5):624-32. Epub  2010 Jan 27. </li>
<p><strong>Multiple imputation for missing data: fully conditional specification  versus multivariate normal imputation. </strong>Lee KJ, Carlin JB. <em>Clinical Epidemiology and Biostatistics  Unit, Murdoch Childrens Research Institute, Royal Children&#8217;s Hospital,  Flemington Road, Parkville, Victoria </em></p>
<p>Statistical analysis in epidemiologic  studies is often hindered by missing data, and multiple imputation is  increasingly being used to handle this problem. In a simulation study, the  authors compared 2 methods for imputation that are widely available in standard  software: fully conditional specification (FCS) or &quot;chained equations&quot;  and multivariate normal imputation (MVNI). The authors created data sets of  1,000 observations to simulate a cohort study, and missing data were induced  under 3 missing-data mechanisms. Imputations were performed using FCS (Royston&#8217;s  &quot;ice&quot;) and MVNI (Schafer&#8217;s NORM) in Stata (Stata Corporation, College  Station, Texas), with transformations or prediction matching being used to  manage nonnormality in the continuous variables. Inferences for a set of  regression parameters were compared between these approaches and a  complete-case analysis. As expected, both FCS and MVNI were generally less  biased than complete-case analysis, and both produced similar results despite  the presence of binary and ordinal variables that clearly did not follow a  normal distribution. Ignoring<br />
  skewness in a continuous covariate led  to large biases and poor coverage for the corresponding regression parameter  under both approaches, although inferences for other parameters were largely  unaffected. These results provide reassurance that similar results can be  expected from FCS and MVNI in a standard regression analysis involving  variously scaled variables.<br />
  PMID: 20106935&nbsp; [PubMed - indexed for MEDLINE]</p>
<p>Free Full Text: <a href="http://aje.oxfordjournals.org/content/171/5/624.long">http://aje.oxfordjournals.org/content/171/5/624.long</a></p>
<li>J Sch Psychol. 2010 Feb;48(1):5-37. </li>
<p><strong>An introduction to modern missing data analyses.</strong> Baraldi AN, Enders  CK. <em>Arizona State University, USA.  Amanda.Baraldi@asu.edu</em></p>
<p>A great deal of recent methodological  research has focused on two modern missing data analysis methods: maximum  likelihood and multiple imputation. These approaches are advantageous to  traditional techniques (e.g. deletion and mean imputation techniques) because  they require less stringent assumptions and mitigate the pitfalls of  traditional techniques. This article explains the theoretical underpinnings of  missing data analyses, gives an overview of traditional missing data techniques,  and provides accessible descriptions of maximum likelihood and multiple  imputation. In particular, this article focuses on maximum likelihood  estimation and presents two analysis examples from the Longitudinal Study of  American Youth data. One of these examples includes a description of the use of  auxiliary variables. Finally, the paper illustrates ways that researchers can  use intentional, or planned, missing data to enhance their research designs.<br />
  PMID: 20006986&nbsp; [PubMed - indexed for MEDLINE]</p>
<li>Int J Epidemiol. 2010 Feb;39(1):118-28. Epub  2009 Oct 25. </li>
<p><strong>Modelling relative survival in the presence of incomplete data: a  tutorial.</strong> Nur U, Shack LG, Rachet B, Carpenter JR, Coleman MP. <em>Cancer Research UK Cancer Survival Group,  London School of Hygiene and Tropical Medicine, London, UK. ula.nur@lshtm.ac.uk</em></p>
<p>BACKGROUND: Missing data frequently  create problems in the analysis of population-based data sets, such as those  collected by cancer registries. Restriction of analysis to records with  complete data may yield inferences that are substantially different from those  that would have been obtained had no data been missing. &#8216;Naive&#8217; methods for  handling missing data, such as restriction of the analysis to complete records  or creation of a &#8216;missing&#8217; category, have drawbacks that can invalidate the  conclusions from the analysis. We offer a tutorial on modern methods for  handling missing data in relative survival analysis.<br />
  METHODS: We estimated relative survival  for 29 563 colorectal cancer patients who were diagnosed between 1997 and 2004  and registered in the North West Cancer Intelligence Service. The method of  multiple imputation (MI) was applied to account for the common example of  incomplete stage at diagnosis, under the missing at random (MAR) assumption.  Multivariable regression with a generalized linear model and Poisson error  structure was then used to estimate the excess hazard of death of the  colorectal cancer patients, over and above the background mortality, adjusting  for significant predictors of mortality.<br />
  RESULTS: Incomplete information on  stage, morphology and grade meant that only 55% of the data could be included  in the &#8216;complete-case&#8217; analysis. All cases could be included after indicator  method (IM) or MI method. Handling missing data by MI produced a significantly  lower estimate of the excess mortality for stage, morphology and grade, with  the largest reductions occurring for late-stage and high-grade tumours, when  compared with the results of complete-case analysis.<br />
  CONCLUSION: In complete-case analysis,  almost 50% of the information could not be included, and with the IM, all  records with missing values for stage were combined into a single &#8216;missing&#8217;  category. We show that MI methods greatly improved the results by exploiting  all the information in the incomplete records. This method also helped to  ensure efficient inferences about survival were made from the multivariate  regression analyses.<br />
  PMID: 19858106&nbsp; [PubMed - indexed for MEDLINE]</p>
<p>Free Full Text: <a href="http://ije.oxfordjournals.org/cgi/pmidlookup?view=long&amp;pmid=19858106">http://ije.oxfordjournals.org/cgi/pmidlookup?view=long&amp;pmid=19858106</a></p>
</ol>
<p></body></p>
]]></content:encoded>
			<wfw:commentRss>http://www.drugepi.org/recently-at-dope/decide-methods-center-cer-scan-december-2011/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Jerry Avorn on Lipitor and the Future of Blockbuster Drugs</title>
		<link>http://www.drugepi.org/recently-at-dope/jerry-avorn-on-lipitor-and-the-future-of-blockbuster-drugs/</link>
		<comments>http://www.drugepi.org/recently-at-dope/jerry-avorn-on-lipitor-and-the-future-of-blockbuster-drugs/#comments</comments>
		<pubDate>Wed, 30 Nov 2011 18:41:47 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Faculty in the Media]]></category>

		<guid isPermaLink="false">http://www.drugepi.org/?p=1367</guid>
		<description><![CDATA[<p>Jerry Avorn, MD, appears on the PBS NewsHour to discuss Lipitor going off-patent and the future of &#8220;blockbuster&#8221; drugs.</p> <p><a href="http://www.pbs.org/newshour/bb/health/july-dec11/lipitor_11-30.html" target="_blank">Watch the interview with Dr. Avorn</a></p>]]></description>
			<content:encoded><![CDATA[<p>Jerry Avorn, MD, appears on the PBS NewsHour to discuss Lipitor going off-patent and the future of &#8220;blockbuster&#8221; drugs.</p>
<p><a href="http://www.pbs.org/newshour/bb/health/july-dec11/lipitor_11-30.html" target="_blank">Watch the interview with Dr. Avorn</a></p>
]]></content:encoded>
			<wfw:commentRss>http://www.drugepi.org/recently-at-dope/jerry-avorn-on-lipitor-and-the-future-of-blockbuster-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Niteesh Choudhry on the Clinical and Economic Impact of Free Medications Post-MI</title>
		<link>http://www.drugepi.org/recently-at-dope/niteesh-choudhry-on-the-clinical-and-economic-impact-of-free-medications-post-mi/</link>
		<comments>http://www.drugepi.org/recently-at-dope/niteesh-choudhry-on-the-clinical-and-economic-impact-of-free-medications-post-mi/#comments</comments>
		<pubDate>Tue, 15 Nov 2011 20:29:28 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Division Research]]></category>
		<category><![CDATA[Faculty in the Media]]></category>

		<guid isPermaLink="false">http://www.drugepi.org/?p=1346</guid>
		<description><![CDATA[<p>At this year&#8217;s American Heart Association meeting, Niteesh Choudhry, MD, PhD, presented a paper he lead authored on the MI FREEE trial. The trial randomized patients to receive free preventive heart medications or their normal insurance coverage after being discharged from the hospital following a myocardial infarction. The paper&#8217;s authors include six other members of [...]]]></description>
			<content:encoded><![CDATA[<p>At this year&#8217;s American Heart Association meeting, Niteesh Choudhry, MD, PhD, presented a paper he lead authored on the MI FREEE trial. The trial randomized patients to receive free preventive heart medications or their normal insurance coverage after being discharged from the hospital following a myocardial infarction. The paper&#8217;s authors include six other members of DoPE.</p>
<p><a href="http://prescriptions.blogs.nytimes.com/2011/11/14/study-finds-co-payments-discourage-drug-treatments/" target="_blank">The New York Times: Study Finds Co-Payments Discourage Drug Treatments</a></p>
<p><a href="http://www.nejm.org/doi/full/10.1056/NEJMsa1107913" target="_blank">The New England Journal of Medicine: Full Coverage for Preventive Medications after Myocardial Infarction</a></p>
<p><a href="http://online.wsj.com/article/APf4499fb7e9cf4b26b1ac16d5ee2a876a.html" target="_blank">Associated Press: Study finds many patients shun free heart drugs</a></p>
<p><a href="http://online.wsj.com/article/SB10001424052970203503204577038433899558246.html?mod=googlenews_wsj" target="_blank">The Wall Street Journal: Heart Attack? What Steps Can Prevent a Second One</a></p>
]]></content:encoded>
			<wfw:commentRss>http://www.drugepi.org/recently-at-dope/niteesh-choudhry-on-the-clinical-and-economic-impact-of-free-medications-post-mi/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

